| Safety: acute leukaemia |
|
Patient or population: children 9 months to 15 years old
Setting: general population
Intervention: MMR vaccine
Comparison: unvaccinated |
| Outcomes |
Anticipated absolute effects* (95% CI) |
Relative effect
(95% CI) |
№ of participants
(studies) |
Certainty of the evidence
(GRADE) |
| Risk of acute leukaemia
amongst unvaccinated
|
Risk of acute leukaemia
amongst vaccinated
|
| Case‐control ‐ acute leukaemia |
Study population |
OR 0.97
(0.76 to 1.24) |
941 cases, 1667 controls
(2 observational studies) |
⊕⊕⊝⊝
LOW |
| 0 per 1000 |
0 per 1000
(0 to 0) |
| Case‐control ‐ acute lymphoblastic leukaemia |
Study population |
OR 0.91
(0.72 to 1.14) |
1375 cases, 2316 controls
(4 observational studies) |
⊕⊕⊝⊝
LOW |
| 0 per 1000 |
0 per 1000
(0 to 0) |
| Case‐control ‐ acute myeloblastic leukaemia |
Study population |
OR 0.56
(0.29 to 1.07) |
62 cases, 1258 controls
(1 observational study) |
⊕⊕⊝⊝
LOW |
| 0 per 1000 |
0 per 1000
(0 to 0) |
| *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; MMR: measles, mumps, rubella vaccine; OR: odds ratio |
|
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. |
